ALLMedicine™ Hypertrophic Cardiomyopathy Center

Jan 13th, 2021 - Obscurin is a giant muscle protein that connects the sarcomere with the sarcoplasmic reticulum, with poorly understood structural and signalling functions. Increasingly, obscurin variants are implicated in the pathophysiology of cardiovascular dis...

Jan 13th, 2021 - Hypertrophic cardiomyopathy (HCM) is an inherited cardiac disease, which has a marked heterogeneity in clinical expression, natural history, and prognosis. HCM is associated with a high prevalence of thromboembolic events (stroke and systemic embo...

Jan 13th, 2021 - Objective: We sought to investigate the possible association of a wide QRS-T angle on the surface EKG and myocardial fibrosis on contrast-enhanced cardiovascular magnetic (CMR) imaging in patients with hypertrophic cardiomyopathy (HCM). Background...

Jan 12th, 2021 - Determine whether the intraoperative three-dimensional left ventricular outflow tract cross-sectional area may be inversely correlated with pressure gradients as a determinant of surgical success after septal myectomy in hypertrophic cardiomyopath...

Jan 12th, 2021 - Tubulin Detyrosination: An Emerging Therapeutic Target in Hypertrophic Cardiomyopathy.|2021|Margulies KB,Prosser BL,|

May 21st, 2019 - Question Is it possible to identify most patients with hypertrophic cardiomyopathy (HCM) at risk of arrhythmic sudden cardiac death (SCD) and to prevent such events with prophylactic implantable cardioverter/defibrillators (ICDs)? Findings In t...

Feb 4th, 2016 - Guidelines for Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy (JCS 2012)　- Digest Version .|2016| ,|diagnosis,physiopathology,therapy,

Aug 31st, 2014 - 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).|2014| ,Elliott PM,Anastasakis A,Borger MA,B...

Nov 18th, 2011 - 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.|2011| , , , , ,|diag...

Nov 14th, 2011 - 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the Ame...

Jan 13th, 2021 - Obscurin is a giant muscle protein that connects the sarcomere with the sarcoplasmic reticulum, with poorly understood structural and signalling functions. Increasingly, obscurin variants are implicated in the pathophysiology of cardiovascular dis...

Jan 13th, 2021 - Hypertrophic cardiomyopathy (HCM) is an inherited cardiac disease, which has a marked heterogeneity in clinical expression, natural history, and prognosis. HCM is associated with a high prevalence of thromboembolic events (stroke and systemic embo...

Jan 13th, 2021 - Objective: We sought to investigate the possible association of a wide QRS-T angle on the surface EKG and myocardial fibrosis on contrast-enhanced cardiovascular magnetic (CMR) imaging in patients with hypertrophic cardiomyopathy (HCM). Background...

Jan 12th, 2021 - Determine whether the intraoperative three-dimensional left ventricular outflow tract cross-sectional area may be inversely correlated with pressure gradients as a determinant of surgical success after septal myectomy in hypertrophic cardiomyopath...

Jan 12th, 2021 - Tubulin Detyrosination: An Emerging Therapeutic Target in Hypertrophic Cardiomyopathy.|2021|Margulies KB,Prosser BL,|

Nov 19th, 2020 - Greater involvement of the patient and family in decision-making, clarity on the role of genetic testing and parameters for team-oriented care, and use of high-volume specialty centers are cornerstones of the first update in almost a decade of the...

Oct 14th, 2020 - Among the landmark presentations at the recent European Society of Cardiology virtual congress was the presentation on the EXPLORER-HCM randomized controlled trial. In this study, simultaneously published in The Lancet, the investigational drug ma...

Oct 14th, 2020 - Among the landmark presentations at the recent European Society of Cardiology virtual congress was the presentation on the EXPLORER-HCM randomized controlled trial. In this study, simultaneously published in The Lancet, the investigational drug ma...

Aug 28th, 2020 - An investigational drug that targets part of the molecular machinery underlying obstructive hypertrophic cardiomyopathy (HCM) can improve both symptoms and functional status in patients with the genetic disorder, suggests a placebo-controlled phas...

Aug 28th, 2020 - An investigational drug that targets part of the molecular machinery underlying obstructive hypertrophic cardiomyopathy (HCM) can improve both symptoms and functional status in patients with the genetic disorder, suggests a placebo-controlled phas...